What the Ozempic and Mounjaro analysis found
Adults with type 2 diabetes in a US insurance-claims analysis had a reported 6 per cent lower risk of major cardiovascular events after increasing their Ozempic dose rather than switching to Mounjaro. According to Healthline, the findings were presented at the 2026 European Association for the Study of Diabetes annual meeting in Milan.
The result is an association, not proof that increasing Ozempic provides better heart protection. Researchers looked back at existing healthcare records rather than randomly assigning patients to the two treatment approaches.
The COMPETE SWITCH Cardiovascular analysis examined records covering 636,525 adults with type 2 diabetes, using Komodo Health’s Healthcare Map, a US claims database with linked laboratory results. The comparison focused on 185,705 people who increased their semaglutide dose and 23,104 who switched to tirzepatide.
Everyone in that comparison had been receiving 1 mg of semaglutide, sold as Ozempic, each week. Researchers compared an increase to 2 mg with a switch to tirzepatide, sold as Mounjaro, at doses up to 15 mg.
The combined outcome included death from any cause, heart attack and stroke. The headline finding therefore should not be read as a separate 6 per cent reduction in each of those outcomes, or specifically in deaths from heart disease.
Healthline’s account does not give absolute event rates, a follow-up duration or a confidence interval for the estimate. It is consequently not possible from that report to say how many fewer events occurred per 100 patients, or to assess the statistical precision of the difference.
How Ozempic and Mounjaro differ
Semaglutide acts on the GLP-1 receptor, while tirzepatide acts on both GLP-1 and GIP receptors. These hormone pathways help regulate blood sugar and appetite, making the medicines relevant to both diabetes treatment and weight management.
Brand names and indications need care. In the UK, Ozempic is a diabetes treatment and Wegovy is the semaglutide brand used for weight management. Mounjaro is authorised for both type 2 diabetes and weight management in eligible patients; Zepbound, mentioned in the US source, is an American tirzepatide weight-management brand.
This analysis addresses a narrower question than which medicine is best overall: what happened when people already taking a particular Ozempic dose increased it or changed drugs. It does not establish the best starting treatment for someone newly prescribed either medicine, or the cardiovascular effects in people without diabetes.
It also concerns a different treatment change from the switch from injections to a Wegovy pill. Findings about weight loss after changing formulations cannot settle the cardiovascular comparison reported here.
What clinicians say about the cardiovascular findings
Mir Ali, medical director of the MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in California, told Healthline that medication adherence might explain part of the finding. He was not involved in the research.
Ali said changing medicines can require time to adjust the dose and reach an appropriate treatment level, potentially affecting disease control during that period. That is a possible explanation, not a mechanism established by the analysis.
He also said the research had not determined why cardiovascular risk differed. Weight loss and effects on hormones involved in metabolism and appetite might contribute, he suggested.
Amit Blumfield, of Manhattan Cardiology in New York, who was also uninvolved in the study, told Healthline that he would generally consider switching where tolerability was a problem. If a medicine remained effective for weight and blood sugar management and was tolerated at higher doses, he would not necessarily recommend a change.
What the findings mean for Ozempic prescribing
Further research is needed to compare the cardiovascular benefits of semaglutide and tirzepatide more fully. The observational result alone does not provide a basis for declaring one medicine preferable for every patient.
For someone already taking Ozempic, the practical decision remains a discussion with their prescriber about treatment response, side effects and the benefits and drawbacks of changing medicines. Healthline’s report does not describe a resulting change to UK prescribing guidance or NHS access rules.
